Addiction to c-MYC in multiple myeloma

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

(2011) W-J Chng et al.   LEUKEMIA

New model systems provide insights into Myc-induced transformation

(2011) A R Wasylishen et al.   ONCOGENE

Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells

(2010) Jin-Jian Lu et al.   BIOCHEMICAL PHARMACOLOGY

Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma

(2009) Ariel Anguiano et al.   JOURNAL OF CLINICAL ONCOLOGY

OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus

(2009) Thea Kristin Våtsveen et al.   LEUKEMIA RESEARCH

Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice

(2008) Jianxia Guo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE